Tg Therapeutics (TGTX) Deferred Taxes (2025 - 2026)
Tg Therapeutics (TGTX) posted quarterly Deferred Taxes of $3.9 million for Q1 2026, down 87.75% quarter-over-quarter from $31.6 million in Q4 2025.
Powered by 
Analysis
Tg Therapeutics (TGTX) Deferred Taxes (2025 - 2026) Analysis & Trends
Tg Therapeutics' Deferred Taxes history runs 2 years deep, the most recent figure standing at $3.9 million for Q1 2026.
- In Q1 2026, Deferred Taxes changed N/A year-over-year to $3.9 million; the TTM figure through Mar 2026 stood at $35.4 million (changed N/A YoY), while the FY2025 annual figure was -$335.1 million, changed N/A from the prior year.
- Deferred Taxes for Q1 2026 stood at $3.9 million, down from $31.6 million in the prior quarter.
- The five-year high for Deferred Taxes was $31.6 million in Q4 2025, with the low at $3.9 million in Q1 2026.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Deferred Taxes (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 138.47 Bn | 130.62 Bn | 2.84 Bn | -69.70 Mn |
| 2 | Regeneron Pharmaceuticals | 85.18 Bn | 77.19 Bn | 3.93 Bn | 194.40 Mn |
| 3 | Argenx Se | 63.38 Bn | 58.19 Bn | 1.37 Bn | - |
| 4 | Moderna | 58.09 Bn | 52.95 Bn | 52.00 Mn | - |
| 5 | Revolution Medicines | 44.33 Bn | 44.33 Bn | - | - |
| 6 | BeOne Medicines | 40.02 Bn | 34.92 Bn | 1.53 Bn | - |
| 7 | Alnylam Pharmaceuticals | 35.57 Bn | 32.27 Bn | 992.69 Mn | 2.66 Mn |
| 8 | Royalty Pharma | 28.45 Bn | 27.61 Bn | - | - |
| 9 | Insmed | 27.48 Bn | 26.32 Bn | 358.27 Mn | - |
| 10 | Tg Therapeutics | 7.97 Bn | 7.29 Bn | 199.14 Mn | 708,000.00 |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 708,000.00 |
| Mar 31, 2026 | 3.86 Mn |
| Dec 31, 2025 | 18.63 Mn |
| Sep 30, 2025 | -366.63 Mn |